Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
about
Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectivesCurrent approaches for optimizing the benefit of biologic therapy in ulcerative colitisPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseThe role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitisUstekinumab for the treatment of Crohn's disease: can it find its niche?Optimizing biologic treatment in IBD: objective measures, but when, how and how often?Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative ColitisNon-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewClinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Update on the Medical Management of Crohn's Disease.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Optimizing biological therapy in Crohn's disease.Use of anti-TNF drug levels to optimise patient management.Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.Therapeutic innovations in inflammatory bowel diseases.Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel DiseaseEmerging therapeutic targets and strategies in Crohn's disease.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
P2860
Q26740356-3FA3B354-6C92-4959-AE80-565B7A6AF384Q26745712-754714C8-6BEF-4113-A0E8-2A189B044A73Q26745721-8364868F-6E88-4214-B463-43893C8425BFQ26748626-1FC29041-C384-4861-83F9-04B951407340Q26771890-FDCBC552-99AB-4FF3-8188-CFD60145CE50Q26775064-CDF3075B-31B7-41BA-BCEB-C4A481D30554Q30235581-73A2690F-7D6F-4BCA-9D69-E32E97A2AD8CQ30248641-78F8695B-3D7D-451B-B509-56DC02D4F231Q37098456-FAF9DAD6-BB5B-4316-AD05-66512AC4CEF8Q37118400-84A323EB-5E2C-4770-9F51-C45F2562FD0CQ37671983-894A0DDB-EEB1-46DD-AAFE-90CE18B07E36Q37672250-AA9F4A79-9133-4ABA-8AD0-7516DC18CB56Q38462602-FCB79FE5-31D7-4041-94B3-403CC5B3F962Q38564877-FF456752-48E2-473C-A359-0E6EC3EC0E7BQ38585634-1977BD9B-AC2E-460F-96B6-CC4DA8E45D57Q38586029-9425AE2D-A08E-470F-B4D1-939F99DD5A61Q38608158-BF02786E-421B-4294-B0D8-E601F4F76472Q38608951-27675182-7BF0-4A8F-B0C1-675E0F3A7FE1Q38609741-8FE81E0E-3CAA-40F6-A009-B7DD93CE7D09Q38618178-64AD9D11-2CB4-4F92-8565-B7AB29774D03Q38619764-46A8748E-785C-4E51-890E-76C07BAFD88BQ38619950-0EED56FD-AB8E-4A02-BD38-093F1DF2A0BFQ38620415-1F75AC92-621F-4C51-8D14-FB682CF3575CQ38633561-44D07194-9B14-4A58-82D6-A9E11332E762Q38669163-8A6B927D-05A4-4E08-B8FE-1D698ABCA91CQ38673082-92497E3F-AAEE-4A0D-BEB2-88F5F8B085DDQ38695300-ED2D5519-AF77-49FA-8E41-0A928CBFA18EQ38695700-FE032489-1DFD-44F2-80BB-FAE8931AE1ACQ38696392-86ADE835-A7C1-4CF1-B69C-984BA576A84DQ38719570-5594A94A-ED5B-4DEA-80D2-312FF8E92F87Q38789642-C53AF0CF-ACE1-40BE-8885-6AF76F7D5082Q38798678-C19BD8ED-0777-4D7A-AEEE-B1C3E5807460Q38814451-8B07A9C7-F58F-48CB-846B-1300F0F687BDQ38822920-80D8F794-DC2F-413B-9ECE-B7D89B51C333Q38826447-56D1EF17-1F4F-4ECF-B2F1-752172F82E2EQ38849974-94514956-482C-4EF7-BE35-E4DC28BD9F36Q38850063-7E9B861A-5E65-4E15-8B12-C5E8F142711FQ38856947-C91B2551-CB1A-4B47-B964-3E0E1838571EQ38881849-BC4E4109-1542-4B63-9188-233CC1E28F12Q38883761-25FD76E3-CECA-4C8C-97E4-E723D1B3CAE5
P2860
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Trough concentrations of infli ...... th inflammatory bowel disease.
@en
Trough concentrations of infli ...... th inflammatory bowel disease.
@nl
type
label
Trough concentrations of infli ...... th inflammatory bowel disease.
@en
Trough concentrations of infli ...... th inflammatory bowel disease.
@nl
prefLabel
Trough concentrations of infli ...... th inflammatory bowel disease.
@en
Trough concentrations of infli ...... th inflammatory bowel disease.
@nl
P2093
P50
P1433
P1476
Trough concentrations of infli ...... th inflammatory bowel disease.
@en
P2093
Gert Van Assche
Griet Compernolle
Marc Ferrante
Paul Rutgeerts
Vera Ballet
P304
P356
10.1053/J.GASTRO.2015.02.031
P407
P577
2015-02-24T00:00:00Z